[
    {
        "category": "company",
        "datetime": 1743525840,
        "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
        "id": 133676059,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=3ff696d9853a86473425700a3f2f46773c6f7ac0d44c8d581d0f2215eeabec14"
    },
    {
        "category": "company",
        "datetime": 1743522637,
        "headline": "Biotech stocks slide as Marks resignation seen being negative for sector",
        "id": 133645467,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration\u2019s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is \u201cnot good for the biotech industry even beyond vaccines.\u201d Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a \u201csignificant negative\u201d for the biopharma and biotech sectors. \u201cNOT GOOD\u201d FOR BIOTECH SECTOR: RBC Capit",
        "url": "https://finnhub.io/api/news?id=254d158cbf2c958ffa39dd784453958618f4931103736807bbadab76abc44dcf"
    },
    {
        "category": "company",
        "datetime": 1743518940,
        "headline": "The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals",
        "id": 133647230,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.",
        "url": "https://finnhub.io/api/news?id=e7c2b00fc77aa546a5b183fed565f429e62d9954f121e950238a866f848b56cb"
    },
    {
        "category": "company",
        "datetime": 1743430200,
        "headline": "Intellia Focuses on Pipeline Development Amid Stiff Competition",
        "id": 133627901,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.",
        "url": "https://finnhub.io/api/news?id=8195ef88c62076e0d29f7e1998b1800e0b7f49a7f07c30bf70afca5baf173fc1"
    },
    {
        "category": "company",
        "datetime": 1743426600,
        "headline": "3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space",
        "id": 133627961,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.",
        "url": "https://finnhub.io/api/news?id=c9571d0a3c4c4d14e33bb28efac4574b91358be920e5e0a8da5ba1fbe0a06304"
    },
    {
        "category": "company",
        "datetime": 1743338531,
        "headline": "Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows",
        "id": 133622806,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other blue chip stocks to invest in at 52-week lows. For the first time since 2023, the S&P 500 was seen [\u2026]",
        "url": "https://finnhub.io/api/news?id=a54495ce7bef0c48ee3c0b81c5f4f7a215a4e9e9410eea3fb227e0ad1eaafd82"
    },
    {
        "category": "company",
        "datetime": 1743306600,
        "headline": "abrdn Life Sciences Investors Q4 2024 Commentary",
        "id": 133594341,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205513/image_1322205513.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=66dc9f2b53ce613484d516524a22eafdccbe115cabd59877c7d52f9cd1ad811b"
    },
    {
        "category": "company",
        "datetime": 1743303000,
        "headline": "abrdn Healthcare Investors Q4 2024 Commentary",
        "id": 133590926,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91598774/image_91598774.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=82f91dbf63848ebe808f64808c8e5edf8521e08d31f59b25f79fc61ada48f984"
    },
    {
        "category": "company",
        "datetime": 1743155082,
        "headline": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
        "id": 133508460,
        "image": "",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=2ec9b46a156413c058393a72e5bee50e867a91233b35571d7b5b27f08d74bd75"
    },
    {
        "category": "company",
        "datetime": 1743154200,
        "headline": "Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials",
        "id": 133508412,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1370321402/image_1370321402.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I rate CRVS stock as a Hold.",
        "url": "https://finnhub.io/api/news?id=74d837da9fa83c9b38f66e46281ecc5bbc772637cb121e0f5b2521cffd46ea9a"
    },
    {
        "category": "company",
        "datetime": 1743154195,
        "headline": "Corvus Pharmaceuticals: Now At Cruising Altitude",
        "id": 133508413,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1148535002/image_1148535002.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in...",
        "url": "https://finnhub.io/api/news?id=1b08225a60a8aeaa240ed02edad15db849102f3d8fd8ba0c97862add3f29bdf2"
    },
    {
        "category": "company",
        "datetime": 1743152439,
        "headline": "RNA Biotechs: Current State And Outlook",
        "id": 133508214,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1355122387/image_1355122387.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with stability and specificity. Explore more details here.",
        "url": "https://finnhub.io/api/news?id=1f3638fe5d94396e4de4d10d757d411c0123cc3cebc9f3478bbed086637c300b"
    },
    {
        "category": "company",
        "datetime": 1743143052,
        "headline": "Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication",
        "id": 133506913,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192921796/image_2192921796.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Intellia\u00e2\u0080\u0099s nex-z gets FDA RMAT for ATTR-CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.",
        "url": "https://finnhub.io/api/news?id=fd3d0a821709e20b4ebf69357265a026042c69cce7110a42e2635aee9e80c498"
    },
    {
        "category": "company",
        "datetime": 1743141600,
        "headline": "Dupixent\u00ae (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)",
        "id": 133505739,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation TARRYTOWN, N.Y. and PARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and",
        "url": "https://finnhub.io/api/news?id=8775044f250d9a4cef6fa2453c01e9141e70e5849b69d258147659055385f929"
    },
    {
        "category": "company",
        "datetime": 1743119100,
        "headline": "Putnam Large Cap Value Fund Q4 2024 Commentary",
        "id": 133504300,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1369582427/image_1369582427.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "While US stocks overall posted a gain in the fourth quarter, value stocks fared differently, posting a modest negative return for the period.",
        "url": "https://finnhub.io/api/news?id=aeb92e66edaac5fe4e65f5b4d5d2bdee7f7625e0a724ba5862044a3ef0a67248"
    },
    {
        "category": "company",
        "datetime": 1743115200,
        "headline": "Putnam U.S. Large Cap Value Equity Concentrated SMA Q4 2024 Commentary",
        "id": 133504074,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323554443/image_1323554443.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "In a challenging quarter for value stocks, the portfolio posted a negative return (-1.70% gross of fees and -2.43% net of fees), slightly outperforming Russell 1000 Value Index.",
        "url": "https://finnhub.io/api/news?id=a8a7a1468e7467634a93b41c26683069850751c35ef84270a54f72cba84f9f81"
    },
    {
        "category": "company",
        "datetime": 1743060600,
        "headline": "Franklin Biotechnology Discovery Fund Q4 2024 Commentary",
        "id": 133467152,
        "image": "",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=743b5137aca60badcb2ace1e5601b3a1d46e916bce67c484c60523c28bfb157b"
    },
    {
        "category": "company",
        "datetime": 1742938731,
        "headline": "Is Regeneron Pharmaceuticals, Inc.\u00a0(REGN) a Promising Biotech Stock According to Wall Street Analysts",
        "id": 133445019,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The biotechnology sector is gaining new momentum with better market [\u2026]",
        "url": "https://finnhub.io/api/news?id=73c118e6969f253b0b221bee4a8034fc66ab752e7b44ce0f0643d4fae76ce268"
    },
    {
        "category": "company",
        "datetime": 1742933100,
        "headline": "Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025",
        "id": 133445020,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the \u2019Investors and Media\u2019 page of Regeneron\u2019s websi",
        "url": "https://finnhub.io/api/news?id=b11a1109ff6abf211a7a5e169ed29e7ea079e7aff3293f9d52f1459eec974953"
    },
    {
        "category": "company",
        "datetime": 1742917860,
        "headline": "UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study",
        "id": 133445021,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.",
        "url": "https://finnhub.io/api/news?id=39aea18a7fc473fc05e18de79b0970a18e3baf109fe88bcce6bbc1ca648b2580"
    },
    {
        "category": "company",
        "datetime": 1742909863,
        "headline": "Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Extremely Profitable Stocks to Buy According to Analyst?",
        "id": 133375749,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best extremely profitable stocks to buy according to analysts. Fed\u2019s Response to Inflation and Growth Challenges We recently covered 10 Best [\u2026]",
        "url": "https://finnhub.io/api/news?id=38d14c0f7eba7c6c7a33ae74d5aedf9c9980a4a8f9e9d6d13200c14b19aa2729"
    },
    {
        "category": "company",
        "datetime": 1742547998,
        "headline": "3 Reasons to Sell REGN and 1 Stock to Buy Instead",
        "id": 133325924,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "What a brutal six months it\u2019s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many shareholders. This might have investors contemplating their next move.",
        "url": "https://finnhub.io/api/news?id=e0ab990a79b7fd3dbf0d38f912ed241ce1b6a7c4ea96b360ca8c720e06daafbc"
    },
    {
        "category": "company",
        "datetime": 1742488920,
        "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
        "id": 133304066,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=f07d209bcc4eadc6963027cee7a95932952429f75be4137de905e72ae94805b6"
    },
    {
        "category": "company",
        "datetime": 1742462400,
        "headline": "Invesco American Franchise Fund Q4 2024 Commentary",
        "id": 133274172,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453695647/image_1453695647.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.",
        "url": "https://finnhub.io/api/news?id=0cd13fc08d4ce6b9816bba245a2003d62ea169e7a9e1c8f3ac7b61ca90aa6b57"
    },
    {
        "category": "company",
        "datetime": 1742461785,
        "headline": "Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack",
        "id": 133325925,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.",
        "url": "https://finnhub.io/api/news?id=e85bac298831e78bf22d36204f1aee651ea7c16900fc03b351b6aff432769054"
    },
    {
        "category": "company",
        "datetime": 1742461500,
        "headline": "Invesco Health Care Fund Q4 2024 Commentary",
        "id": 133273550,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.",
        "url": "https://finnhub.io/api/news?id=8f81827abb6ec00be306ef52a83e31acbe2c243bf3d6f7d992305822a81d2a8e"
    },
    {
        "category": "company",
        "datetime": 1742402520,
        "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
        "id": 133275479,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
        "url": "https://finnhub.io/api/news?id=97d9c07763cffe3fd11deddee3c3bddaa77b5a1b64f3d64b3704e1952069b64b"
    },
    {
        "category": "company",
        "datetime": 1742290681,
        "headline": "Regeneron Pharmaceuticals (REGN): Among the Best Biotech Stocks to Buy According to Billionaires",
        "id": 133325926,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best biotech stocks. Although biotech stocks had a \u201cchallenging\u201d year in 2024, JPMorgan believes that some of the industry\u2019s companies [\u2026]",
        "url": "https://finnhub.io/api/news?id=098206ae429845699f38c4de898e175151c99e34dccc561c5e456017fffe9514"
    },
    {
        "category": "company",
        "datetime": 1742278206,
        "headline": "United States v. Regeneron: Where \"But-For\" Art Thou, Romeo?",
        "id": 133215550,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "On February 18, the US Court of Appeals for the First Circuit issued its long-awaited decision in United States v. Regeneron Pharmaceuticals, Inc.1joining a high-profile circuit split on the extent of...",
        "url": "https://finnhub.io/api/news?id=c2a7d804c35479a5046f64ad829ea8a185e73b7d6a1fd5454bfebbb95b34aaae"
    },
    {
        "category": "company",
        "datetime": 1742263623,
        "headline": "Jim Cramer Wants You to \u2018Own\u2019 Regeneron Pharmaceuticals (REGN) Shares",
        "id": 133325927,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently published a list of Jim Cramer\u2019s Latest Stock Moves: Top 10 Calls. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stands against other stocks that Jim Cramer discusses. Jim Cramer in a recent program on CNBC expressed his frustration over the recent market selloff following [\u2026]",
        "url": "https://finnhub.io/api/news?id=7804706c157ae0e9954f323cc3a193b2b854f79a68251096dfdcc41bc7cd6ec4"
    },
    {
        "category": "company",
        "datetime": 1742252303,
        "headline": "Why Organon Is A Top Pick For Income Investors",
        "id": 133211092,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1472143072/image_1472143072.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.",
        "url": "https://finnhub.io/api/news?id=697fea97f771736843602e4ccd567ee09566458d477be611dbdde99159b46b96"
    },
    {
        "category": "company",
        "datetime": 1742232152,
        "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Shares Dip 1% Despite Positive Dupixent Trial Results",
        "id": 133325928,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing serious health conditions. Despite these promising developments, the company's shares saw a 1% decline over the past month, reflecting broader market challenges. The Nasdaq Composite, where Regeneron is listed, has been impacted by ongoing economic uncertainties and political factors, leading to...",
        "url": "https://finnhub.io/api/news?id=8df4fee9807db2d1f8a2597be88cf6df9416d1858d2f906d90de07d3f850bd61"
    },
    {
        "category": "company",
        "datetime": 1742216482,
        "headline": "2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off",
        "id": 133325845,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
        "url": "https://finnhub.io/api/news?id=87f7b261071dbfce06fedf6dcbab72f105692c608bbbd39d42f1bfcfc6874589"
    },
    {
        "category": "company",
        "datetime": 1741970460,
        "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
        "id": 133222588,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=e4158f6f5f8d20c82ed7a730688f4f72822e4c96154c22cdc7fb81ec5e2705a7"
    },
    {
        "category": "company",
        "datetime": 1741966676,
        "headline": "Jim Cramer On Regeneron Pharmaceuticals Inc. (REGN) \u2013 \u201cI Want You to Own It\u201d",
        "id": 133186686,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against other stocks that Jim Cramer discussed recently. Jim Cramer kicked off his latest episode of Mad Money by highlighting the wild [\u2026]",
        "url": "https://finnhub.io/api/news?id=4885e243eb1354b42c0b58a3023e670330003ec79062a0445a84914bbb976a4d"
    },
    {
        "category": "company",
        "datetime": 1741945228,
        "headline": "Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?",
        "id": 133168922,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166178/image_168166178.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.",
        "url": "https://finnhub.io/api/news?id=5b375f110a67ecf83936bf4bee953fea25a4043611ffce7bcba7609d1cc03b8c"
    },
    {
        "category": "company",
        "datetime": 1741804190,
        "headline": "Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Pharma Stock to Buy According to Hedge Funds?",
        "id": 133186687,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in [\u2026]",
        "url": "https://finnhub.io/api/news?id=73d8633fe73031827e09922ce585b40aa78c6bbae474347c4f64a38757c617b0"
    },
    {
        "category": "company",
        "datetime": 1741797720,
        "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
        "id": 133222590,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=a0fbe84336b26b75948ad7cc0b08876e3c26673cbe7d5d8a3ebc714370527cea"
    },
    {
        "category": "company",
        "datetime": 1741793414,
        "headline": "Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report?",
        "id": 133185498,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=f297b0f96ecf5627c1bb5d0f1adf3831195761050b8de52bda165ebfa870c982"
    },
    {
        "category": "company",
        "datetime": 1741777200,
        "headline": "Invesco Summit Fund Q4 2024 Commentary",
        "id": 133149564,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149067144/image_2149067144.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.",
        "url": "https://finnhub.io/api/news?id=b6b7a9b04968ef2dc0344a2d4b9eee78d705f6cf8640e8b584642a4d569b9f25"
    },
    {
        "category": "company",
        "datetime": 1741747800,
        "headline": "Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem",
        "id": 133186689,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Matteo Paz, 18, of Pasadena, California, won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.'s oldest and most prestigious science and math competition for high school seniors.",
        "url": "https://finnhub.io/api/news?id=b81e8d29e38f07a2559623b74de4218f1a545ca9ff89f52814cae3225dbaa957"
    },
    {
        "category": "company",
        "datetime": 1741743120,
        "headline": "Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem",
        "id": 133186690,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "$250,000 top award goes to Matteo Paz in America\u2019s longest running and most distinguished science and math competitionTARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Matteo Paz,18, of Pasadena, CA, won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.\u2019s oldest and most prestigious science and math competition for high school seniors. Now in its 84th",
        "url": "https://finnhub.io/api/news?id=6ab3987e360dd77b2070dc006da1cc6fdbd763dedea17275ecd8629db84b160e"
    },
    {
        "category": "company",
        "datetime": 1741688729,
        "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript",
        "id": 133135164,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ETCompany ParticipantsRyan...",
        "url": "https://finnhub.io/api/news?id=a16ffc235bdd85af0ee56359e668467837b874aaf76788a5918321c6f04a65cf"
    },
    {
        "category": "company",
        "datetime": 1741649368,
        "headline": "Regeneron Pharmaceuticals, Inc. (REGN): Hedge Funds Are Bullish On This Oversold Blue Chip Stock Now",
        "id": 133186691,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 11 Oversold Blue Chip Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other oversold blue chip stocks. The uncertainty related to the tariff announcements continues to influence Wall Street. Reuters reported that [\u2026]",
        "url": "https://finnhub.io/api/news?id=e66ffbb18f38ae65a49626a631ca1d2a8322aefd5ba7daf729fda6b05a29e919"
    },
    {
        "category": "company",
        "datetime": 1741642380,
        "headline": "S&P 500 Gains and Losses Today: Index Tumbles as Economic Concerns Intensify",
        "id": 133186692,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "The S&P 500 dropped 2.7% on Monday, March 10, as U.S. tariffs and government job cuts heightened economic uncertainty and provoked recession concerns.",
        "url": "https://finnhub.io/api/news?id=48a630c88df976b42e4116870838310f3361cc29286608c2addb5f7206222087"
    },
    {
        "category": "company",
        "datetime": 1741625163,
        "headline": "REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm",
        "id": 133127690,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. for violations of \u00a7\u00a710 and 20 of the...",
        "url": "https://finnhub.io/api/news?id=31c953d81e1c77528ccd384bfc81361b296a8f9b8f6b583f3ce2dec3723389a4"
    },
    {
        "category": "company",
        "datetime": 1741601411,
        "headline": "First Circuit Adopts But-For Causation Standard For Kickback-Premised False Claims Act Actions",
        "id": 133117647,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "On 18 February 2025, the First Circuit Court of Appeals issued its decision in\u00a0United States v. Regeneron Pharmaceuticals, Inc., determining that \u201cbut-for\u201d causation is the proper standard for...",
        "url": "https://finnhub.io/api/news?id=895f85e1eee9318c1273d51f4433cdf21f5c5601e3ec8c213f9b6e2da9796a8b"
    },
    {
        "category": "company",
        "datetime": 1741585582,
        "headline": "REGN LAWSUIT ALERT: The Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline",
        "id": 133116200,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
        "url": "https://finnhub.io/api/news?id=bb6a3f1583ab6314c8e4dc3e551129438778f74db4e1cb792483957a48cd5f73"
    },
    {
        "category": "company",
        "datetime": 1741515600,
        "headline": "1 Dividend Stock Down 30% to Buy and Hold for the Next Decade",
        "id": 133186693,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year.  Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer.  The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise.",
        "url": "https://finnhub.io/api/news?id=bfe43119fdec1c0469dadd3818f5bd019208422bf10292ddc9bc6afdc7f55309"
    },
    {
        "category": "company",
        "datetime": 1741456800,
        "headline": "Dupixent\u00ae (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD",
        "id": 133186694,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placebo Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the U.S. and the Europ",
        "url": "https://finnhub.io/api/news?id=f12ee61898907f2e2a4c5933fde75c0c842a107e330ac5a10dd568b28d6cfb8a"
    },
    {
        "category": "company",
        "datetime": 1741438800,
        "headline": "Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented At Aad",
        "id": 133107875,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "Regeneron Pharmaceuticals, Inc. and Sanofi announced Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent in adults with moderate-to-severe bullous...",
        "url": "https://finnhub.io/api/news?id=2cb82dc7961c932174b1da8fda0c184ec0b2785e92b6279d298aa5fa8cacb646"
    },
    {
        "category": "company",
        "datetime": 1741438800,
        "headline": "Regeneron Pharmaceuticals, Inc. and Sanofi Presents Positive Results from the Pivotal ADEPT Phase 2/3 trial",
        "id": 133107874,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "Regeneron Pharmaceuticals, Inc. and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe bullous...",
        "url": "https://finnhub.io/api/news?id=93098218b3c4e1bd265b8f3ec6264627789c2bd83d87c1f96c704b336e57e094"
    },
    {
        "category": "company",
        "datetime": 1741365660,
        "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains",
        "id": 133155193,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains",
        "url": "https://finnhub.io/api/news?id=a333d19db878f507ab74a1faca7ee14a99e055f9a1e9dcdbd9691e6ffd9c0931"
    },
    {
        "category": "company",
        "datetime": 1741361764,
        "headline": "REGN Deadline: REGN Investors with Losses in Excess of $100K Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit",
        "id": 133100135,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, March 7, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. between November 2, 2023 and October 30,...",
        "url": "https://finnhub.io/api/news?id=43f337a7623fcea3af67a4d5e5168093a0f6488ed2370ffb5312b5e407cc0009"
    },
    {
        "category": "company",
        "datetime": 1741348924,
        "headline": "Deadline Soon: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit",
        "id": 133091430,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "The Law Offices of Frank R. Cruz reminds investors of the upcoming March 10, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors...",
        "url": "https://finnhub.io/api/news?id=41db90c04be8d6bb808d4cbaa9aa33a277077b8c387a87b631858b274f969e7a"
    },
    {
        "category": "company",
        "datetime": 1741334340,
        "headline": "The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals",
        "id": 133186695,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.",
        "url": "https://finnhub.io/api/news?id=24b2004c0e3a698a7c298fff5733cee9a950cc7ee110669e8566c987863a6fab"
    },
    {
        "category": "company",
        "datetime": 1741278672,
        "headline": "Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?",
        "id": 133186696,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=125827510944554debb8bd8f2ff462780dd7bac1e8af07af10e764a89f99e85d"
    },
    {
        "category": "company",
        "datetime": 1741267020,
        "headline": "Fidelity Fund Q4 2024 Review",
        "id": 133067501,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688767071/image_1688767071.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "For the three months ending December 31, 2024, the fund's Retail Class shares gained 1.53%, versus the 2.41% result of the benchmark S&P 500\u00c2\u00ae index. Read more here.",
        "url": "https://finnhub.io/api/news?id=f6c7965a57a378b7c3260bdbdf6042c90eb3e91682e79297f7fef9b0c870fcc9"
    },
    {
        "category": "company",
        "datetime": 1741262468,
        "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit",
        "id": 133064478,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "LOS ANGELES, March 6, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Regeneron...",
        "url": "https://finnhub.io/api/news?id=e64056ca9d6641a0eb0eb03b09061615069e233a1713a42ab11f5f5e6f6bd94a"
    },
    {
        "category": "company",
        "datetime": 1741259703,
        "headline": "Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential",
        "id": 133062916,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406386094/image_1406386094.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Ocular Therapeutix's Axpaxli targets wet AMD with long-acting treatment. Click here to find out why OCUL stock is a Strong Buy.",
        "url": "https://finnhub.io/api/news?id=a51594b9ae048ef8f7a200dc1e3b81c8596f315d4bd7aa3e652045aba007700a"
    },
    {
        "category": "company",
        "datetime": 1741239981,
        "headline": "Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN",
        "id": 133050842,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
        "url": "https://finnhub.io/api/news?id=2eb358139fc146759d0485fcc24d03865bf16d529017af6b09143ed9fb87c250"
    },
    {
        "category": "company",
        "datetime": 1741172645,
        "headline": "SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals",
        "id": 133015631,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "Faruqi & Faruqi, LLP Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired...",
        "url": "https://finnhub.io/api/news?id=31f02ac30e7a34982c0285d30b5b8b4ac170335a826c46e399de1d01db46ef04"
    },
    {
        "category": "company",
        "datetime": 1741163644,
        "headline": "CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ",
        "id": 133014806,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "PHILADELPHIA, March 5, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. on behalf of purchasers...",
        "url": "https://finnhub.io/api/news?id=e23f5f64daf86caac122e453bdbd9187fa994c6e7b97e520293a0f6efc3d14b7"
    },
    {
        "category": "company",
        "datetime": 1741097493,
        "headline": "Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 45th Annual Health Care Conference (Transcript)",
        "id": 132979556,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) TD Cowen 45th Annual Health Care Conference March 4, 2025 11:50 AM ETCompany ParticipantsMarion McCourt - EVP,...",
        "url": "https://finnhub.io/api/news?id=4cdc77ea3ce7facb56a979bb6c03fffe6322e5e88aa098d80a242d252bd27b5d"
    },
    {
        "category": "company",
        "datetime": 1741084029,
        "headline": "Is Regeneron Pharmaceuticals, Inc. (REGN) the Worst Performing Large Cap Stock to Buy According to Analysts?",
        "id": 133186697,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently published a list of 10 Worst Performing Large Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other worst performing large cap stocks to buy according to analysts. How Did The Market Perform in Q4 2024? On [\u2026]",
        "url": "https://finnhub.io/api/news?id=4cd5a13257bb7e667f215893d728788c2b291f1bcf06410465966eb03972fb2c"
    },
    {
        "category": "company",
        "datetime": 1741067181,
        "headline": "Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)",
        "id": 132972891,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, March 4, 2025 /PRNewswire/ --\u00a0Levi &\u00a0Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
        "url": "https://finnhub.io/api/news?id=a2631e25ecfd50fa5a2d22ef695c0dbf3be261c720343f2b9e1619c96e2b75b0"
    },
    {
        "category": "company",
        "datetime": 1741032000,
        "headline": "Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug",
        "id": 133186698,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.",
        "url": "https://finnhub.io/api/news?id=417b3e3da6a566182ab942f592659bed9e208ba861c847d6743357d920bd0d4b"
    },
    {
        "category": "company",
        "datetime": 1741020120,
        "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
        "id": 132986271,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=2cc9f045221c4a81c2babd90f21b60a082536b11f9fff90a7003594d7255cc09"
    },
    {
        "category": "company",
        "datetime": 1741007765,
        "headline": "Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN",
        "id": 132955287,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc.\u00a0 . Such investors are advised to contact Danielle...",
        "url": "https://finnhub.io/api/news?id=8ef25b684910a7e07216b908c7568d961c179a7ac3ac0724bcffdc5509f86bf1"
    },
    {
        "category": "company",
        "datetime": 1740980781,
        "headline": "Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN",
        "id": 132950607,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
        "url": "https://finnhub.io/api/news?id=a75bad2d89c6addcf52480b3388bcaab984b372ce200d14e2a84637b4cc8ed86"
    },
    {
        "category": "company",
        "datetime": 1740920463,
        "headline": "REGN IMPORTANT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action - REGN",
        "id": 132944054,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. between November 2, 2023 and October 30, 2024, both dates inclusive , of...",
        "url": "https://finnhub.io/api/news?id=09d1ec7adbc943bc6725b1dd10ba569134d7f9b121b508404463acb58be26d6a"
    },
    {
        "category": "company",
        "datetime": 1740904387,
        "headline": "Invest In A New Biotech Bull Market With XBI And IBB",
        "id": 132943007,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215526952/image_1215526952.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Biotech stocks may be primed for a long-term bull run. Learn why IBB, XBI, and macro trends like rate cuts make biotech an attractive sector now.",
        "url": "https://finnhub.io/api/news?id=3edf6e48bd25aa568b9ee4bde4307faaa0b7ac715a16ade17f41d2be3765f8a9"
    },
    {
        "category": "company",
        "datetime": 1740837362,
        "headline": "REGN DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action - REGN",
        "id": 132938740,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. between November 2, 2023 and October 30, 2024, both dates inclusive , of...",
        "url": "https://finnhub.io/api/news?id=a8277b7c509b61fcbca3efc78b2fe12aea8b329d94316ef13736fb7bcadc6137"
    },
    {
        "category": "company",
        "datetime": 1740750663,
        "headline": "REGN FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action - REGN",
        "id": 132907222,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. between November 2, 2023 and October 30, 2024, both dates inclusive , of...",
        "url": "https://finnhub.io/api/news?id=4dd25f261582870f30a082299ed52baaa87166c05a800850a8de254b42a1cda3"
    },
    {
        "category": "company",
        "datetime": 1740744000,
        "headline": "Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma",
        "id": 133186699,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhib",
        "url": "https://finnhub.io/api/news?id=f0828ef146c1095e2ae6769d2fb772326ec77cce5331a42dd222b842e28b6c98"
    },
    {
        "category": "company",
        "datetime": 1740729014,
        "headline": "Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma",
        "id": 132904954,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "By Colin Kellaher Regeneron Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended conditional marketing approval of linvoseltamab for...",
        "url": "https://finnhub.io/api/news?id=279dd71a6e8a91f59f435dab37fdf9bef0c8eeb5d1a9b0dc0cb480ce58bf8c53"
    },
    {
        "category": "company",
        "datetime": 1740726000,
        "headline": "Drug Stocks Are the New Safe Bet in a Shaky Market",
        "id": 132907806,
        "image": "",
        "related": "REGN",
        "source": "DowJones",
        "summary": "Drug Stocks Are the New Safe Bet in a Shaky Market",
        "url": "https://finnhub.io/api/news?id=9cbf52ef07edbc5bfcfb2610a217677b7f12f0522f3e65f5864ff7326854f3b8"
    },
    {
        "category": "company",
        "datetime": 1740721580,
        "headline": "Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN",
        "id": 132904212,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Feb. 28, 2025 /PRNewswire/ -- Levi &\u00a0Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
        "url": "https://finnhub.io/api/news?id=c4a84a2ec0b074fa4f27819e68bfc892f57e80399cde905b9c914a19f05c0a0a"
    },
    {
        "category": "company",
        "datetime": 1740712214,
        "headline": "First Circuit Embraces More Restrictive View Of False Claims Act Kickback Enforcement Provision",
        "id": 132903420,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "The United States Court of Appeals for the First Circuit's opinion in United States v. Regeneron Pharmaceuticals, Inc. has sharpened the circuit split for demonstrating the effect of a kickback on...",
        "url": "https://finnhub.io/api/news?id=fb14699ffcd87fbba038a40e4581a743f7027d653e54ec2e8c40e77543bf5d05"
    },
    {
        "category": "company",
        "datetime": 1740712214,
        "headline": "First Circuit Adopts \"But For\" Causation Standard Under The Anti-Kickback Statute, Paving The Way For Potential Supreme Court Review",
        "id": 132903419,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "Last week, the First Circuit Court of Appeals issued its long-awaited decision in United States v. Regeneron Pharmaceuticals1 with significant implications for health care companies facing allegations...",
        "url": "https://finnhub.io/api/news?id=b9f77e7d7833b0f82bfe08bbdac0df3bccc9702095091c23e2484988b89902e4"
    },
    {
        "category": "company",
        "datetime": 1740712213,
        "headline": "Circuit Split Deepens On Anti-Kickback Statute's Causation Standard",
        "id": 132903422,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "Introduction: In its recent decision in United States v. Regeneron Pharmaceuticals, Inc., the United States Court of Appeals for the First Circuit deepened an existing federal circuit court split...",
        "url": "https://finnhub.io/api/news?id=c409206c220709a74146e0a28f5958b0ae2bd0da84c2c0349cef538fbd58429e"
    },
    {
        "category": "company",
        "datetime": 1740658663,
        "headline": "Regeneron makes second bid for blood cancer therapy approval",
        "id": 133186700,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "The FDA will issue a decision on odronextamab\u2019s accelerated approval in relapsed/refractory follicular lymphoma by 30 July 2025.",
        "url": "https://finnhub.io/api/news?id=a32b7c535439748056f6a16c7f873f63d0765a9f116474fd8ff4df4d0300653a"
    },
    {
        "category": "company",
        "datetime": 1740635180,
        "headline": "Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact The Gross Law Firm about pending Class Action - REGN",
        "id": 132898624,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of\u00a0Regeneron Pharmaceuticals, Inc. . ...",
        "url": "https://finnhub.io/api/news?id=ea079fb578358a3abfb42f8fcad56095850797a55138b22a030de211f1df741f"
    },
    {
        "category": "company",
        "datetime": 1740588060,
        "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
        "id": 132886653,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
        "url": "https://finnhub.io/api/news?id=6e093d1e81701fc26eb860cc4d9551d7f50ced34ddc9f94342b57c22d452ff84"
    },
    {
        "category": "company",
        "datetime": 1740571200,
        "headline": "Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma",
        "id": 133186701,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "FDA decision expected by July 30, 2025TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. The target action date for the FDA decision is July 30, 2025. Acceptance of the BLA resubmission fo",
        "url": "https://finnhub.io/api/news?id=b29b7278b385c0491d899661f96bcf456606f82362354fe0e60941dfe8b46923"
    },
    {
        "category": "company",
        "datetime": 1740561344,
        "headline": "Merck's Oncology Strength: Beating Wall Street Again",
        "id": 132878313,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/151810706/image_151810706.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.",
        "url": "https://finnhub.io/api/news?id=48cc045b6210dbf5fc551d979a18cc216581d878f6df5c6d273d0c4b6879a62b"
    },
    {
        "category": "company",
        "datetime": 1740556753,
        "headline": "Regeneron : FDA Accepts Odronextamab Lymphoma Drug Resubmission",
        "id": 132877816,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "By Colin Kellaher Regeneron Pharmaceuticals said the Food and Drug Administration has accepted for review its resubmitted application seeking approval of odronextamab for certain patients with...",
        "url": "https://finnhub.io/api/news?id=f6fa92c079f2f75f6414bf7ca2b412b40c3927638cf660689e0f087c4fc06c4d"
    },
    {
        "category": "company",
        "datetime": 1740555780,
        "headline": "Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission",
        "id": 132886654,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission",
        "url": "https://finnhub.io/api/news?id=fb15811bf46f960ea95a122b3b432d791f4339a82d03a973b2c112d690d2a6dc"
    },
    {
        "category": "company",
        "datetime": 1740539286,
        "headline": "Anti-Kickback Statute Premised False Claims Cases: The \"But For\" Causation Standard Finds Support From First Circuit",
        "id": 132876165,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "It's now 3-1, with the First Circuit aligning with the Sixth and Eighth Circuits finding the meaning of the words resulting from \u2014 as used in a 2010 amendment to the federal Anti-Kickback Statute...",
        "url": "https://finnhub.io/api/news?id=e717d30805babe93b6abb6f3ab3379f6f75be69dda50c6cec2775ab2b500c161"
    },
    {
        "category": "company",
        "datetime": 1740504371,
        "headline": "Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts",
        "id": 133186702,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. The Stock Market Under Trump Admin While stocks initially fell based on worries regarding Trump tariffs on [\u2026]",
        "url": "https://finnhub.io/api/news?id=15fd8c457779b2f107fb19894c071db68b9834d285a31d050bf4d3565ef54a6a"
    },
    {
        "category": "company",
        "datetime": 1740502877,
        "headline": "REGN Deadline: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit",
        "id": 132873411,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. between November 2, 2023 and October 30,...",
        "url": "https://finnhub.io/api/news?id=ec14cd730e3dbb3008af95c5167a0abb23c6aefb0e60af1c1a808b22874fb0a8"
    },
    {
        "category": "company",
        "datetime": 1740501720,
        "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
        "id": 132886655,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
        "url": "https://finnhub.io/api/news?id=c13a7f3078f1729ca098d8c4f9c114feb54ee5339e47b1326be8271b37b515bb"
    },
    {
        "category": "company",
        "datetime": 1740500046,
        "headline": "Big Pipeline Updates From Kiniksa Pharmaceuticals",
        "id": 132873156,
        "image": "https://static.seekingalpha.com/uploads/2025/2/25/4987661-17404994967854137_origin.png",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Kiniksa is shifting to next-gen IL-1 antibodies for recurrent pericarditis. Click here to read more on how this impacts KNSA stock in 2025 and beyond.",
        "url": "https://finnhub.io/api/news?id=eb216098eab1a82abe31410796add4295d490556b8847e2e4dd9f41052a78823"
    },
    {
        "category": "company",
        "datetime": 1740467350,
        "headline": "First Circuit Clarifies \"Resulting From\" Standard Under Anti-Kickback Statute, Reshaping False Claims Act Litigation",
        "id": 132869930,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "The United States Court of Appeals for the First Circuit issued a pivotal ruling earlier this week, finding that in order to establish falsity in a False Claims Act case premised on Anti-Kickback...",
        "url": "https://finnhub.io/api/news?id=25eb8de78f9f2653fe03ddc864b639c9853ebf2c8fb0df2ada77b1d9acfe490c"
    },
    {
        "category": "company",
        "datetime": 1740462379,
        "headline": "Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN",
        "id": 132869356,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
        "url": "https://finnhub.io/api/news?id=ea34027120710c3e48cd46ac3f95566a403a4817876a2d483fa475ab4c16c184"
    },
    {
        "category": "company",
        "datetime": 1740427200,
        "headline": "Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial",
        "id": 133186703,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing Speech and development progress followed dramatic improvements in hearing in first child treated in the trial TARRYTOWN, N.Y., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to varia",
        "url": "https://finnhub.io/api/news?id=4c044b4707d0041a4e7a506a38a503ef75791195a738b3c1c04686c43f9d8187"
    },
    {
        "category": "company",
        "datetime": 1740419174,
        "headline": "Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts",
        "id": 133186704,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best growth stocks to invest in according to analysts. Companies experiencing above-average earnings growth, which is often fueled by innovations [\u2026]",
        "url": "https://finnhub.io/api/news?id=466a9b27878afeb432685d96c8403be7498918be6b54ea69270e8eebb68b2bfd"
    },
    {
        "category": "company",
        "datetime": 1740415320,
        "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
        "id": 132886656,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
        "url": "https://finnhub.io/api/news?id=43464f54fd397d8c1dd7022300e53c696419d4a8ad7182008722827ec955a990"
    },
    {
        "category": "company",
        "datetime": 1740390360,
        "headline": "The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis",
        "id": 133186705,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Merck, Sanofi, Regeneron and Ionis are included in this Analyst Blog.",
        "url": "https://finnhub.io/api/news?id=ee8a69fab3dae0ec98cb78efd2a8455e4ce7ea63b58ccbeb936f4112e253be99"
    },
    {
        "category": "company",
        "datetime": 1740373987,
        "headline": "First Circuit Adopts Defense-Friendly \"But-For\" Causation Standard For AKS-Predicated FCA Claims",
        "id": 132862193,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "In a unanimous panel opinion filed on February 18, 2025, the First Circuit held that False Claims Act cases predicated on violations of the Anti-Kickback Statute ,1\u00a0 require proof that alleged...",
        "url": "https://finnhub.io/api/news?id=fafcd1a81177772033adeb7bcb8e2385da98a853ad21fb26451b814813e4a81f"
    },
    {
        "category": "company",
        "datetime": 1740359588,
        "headline": "First Circuit Adopts \"But-For\" Causation Standard For False Claims Act Cases Based On Anti-Kickback Statute Violations",
        "id": 132861043,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "In United States v. Regeneron Pharmaceuticals, Inc., the First Circuit joined the emerging majority view that False Claims Act claims based on violations of the Anti-Kickback Statute require a...",
        "url": "https://finnhub.io/api/news?id=1862d70beb7e8a2ea651eb5f537726426def0e980d7c04f5a074ea1992cbc57a"
    },
    {
        "category": "company",
        "datetime": 1740341302,
        "headline": "Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders",
        "id": 132859989,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/951515174/image_951515174.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Kodiak Sciences uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Read why KOD stock is a Buy.",
        "url": "https://finnhub.io/api/news?id=5818f876ea70b90209b9cd686ce77fbf018b0f585a7a86d113d830306f3a3124"
    },
    {
        "category": "company",
        "datetime": 1740149520,
        "headline": "American Century Ultra Fund Q4 2024 Commentary",
        "id": 132829638,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1990350865/image_1990350865.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "The reelection of former President Donald Trump initially pleased investors who had worried about another protracted legal battle regarding the election\u00e2\u0080\u0099s results.",
        "url": "https://finnhub.io/api/news?id=28432d454250134095abc28e662127b36c52d783df7854ae725ef5757b7abdfa"
    },
    {
        "category": "company",
        "datetime": 1740116781,
        "headline": "Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN",
        "id": 132826800,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
        "url": "https://finnhub.io/api/news?id=c447e8e8449ac3c2dd1d387a19740671fbe3171adf70e3653b5c7a9ea0082ae4"
    },
    {
        "category": "company",
        "datetime": 1740114609,
        "headline": "False Claim Act Liability Under Anti-Kickback Statute Requires But-For Causation: First Circuit Narrows Liability In Growing Circuit Split",
        "id": 132826598,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "Key Takeaways: ...",
        "url": "https://finnhub.io/api/news?id=d3ef1e0cb44bedf4de7ca2d03a06252d3c793f093c6d1c236710c29362967ed0"
    },
    {
        "category": "company",
        "datetime": 1740098405,
        "headline": "REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit",
        "id": 132825225,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of\u00a0Regeneron Pharmaceuticals, Inc. between November 2, 2023 and October...",
        "url": "https://finnhub.io/api/news?id=72696b65c4697aa9d6c74e91a3a1bd59a02b6c75b42ae6bccb808ef10b7e9e23"
    },
    {
        "category": "company",
        "datetime": 1740051546,
        "headline": "Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN",
        "id": 132807576,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "Faruqi & Faruqi, LLP Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their OptionsIf you...",
        "url": "https://finnhub.io/api/news?id=f329b6bb65c0ac25188cc05fcf559c1b337c08e9346fff9cf42c8c58030c2ffe"
    },
    {
        "category": "company",
        "datetime": 1740045900,
        "headline": "Allspring Disciplined U.S. Core Fund Q4 2024 Commentary",
        "id": 132803150,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250588879/image_1250588879.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "The Allspring Disciplined U.S. Core Fund returned 4.18% for the quarter. The benchmark S&P 500 Index returned 2.41%. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=927c4aff26a54e36fea7c6399f31ae9ed3db78418f1545245045452361898007"
    },
    {
        "category": "company",
        "datetime": 1740030382,
        "headline": "Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN",
        "id": 132794851,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of\u00a0Regeneron Pharmaceuticals, Inc. . ...",
        "url": "https://finnhub.io/api/news?id=c8492229c1e6c88631d063069b448946947120e2c8e4f2c016053927090c5ce7"
    },
    {
        "category": "company",
        "datetime": 1739965542,
        "headline": "Regeneron Pharmaceuticals - Dupixent sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid",
        "id": 132787527,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "TARRYTOWN, PARIS - Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License...",
        "url": "https://finnhub.io/api/news?id=841c9b7882bdbe76075e3bc2c33515d1c4f637462a851c032b59c8b664e416a7"
    },
    {
        "category": "company",
        "datetime": 1739896075,
        "headline": "FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea",
        "id": 132819273,
        "image": "https://www.investopedia.com/thmb/_fzcBDUGzyt0jmJjbqzFccuV2Ts=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2191898791-608600ef24ab42e1af0e5e78fe1e808d.jpg",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders, which could compete with Regeneron Pharmaceuticals\u2019 Eylea.",
        "url": "https://finnhub.io/api/news?id=ce9e5204fcd6b464e97c5c12fdb560bf97b2543068d030c7e56828ab31bc6b3a"
    },
    {
        "category": "company",
        "datetime": 1739882400,
        "headline": "SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag",
        "id": 132819274,
        "image": "https://media.zenfs.com/en/zacks.com/5bd570f285e4b6d4e9b1a8c6dc8600e6",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.",
        "url": "https://finnhub.io/api/news?id=2ec98057da2efefeee778a7abca5148105192f0b757b821abb068185ad82d0f4"
    },
    {
        "category": "company",
        "datetime": 1739881076,
        "headline": "FDA to review Sanofi and Regeneron\u2019s Dupixent sBLA for bullous pemphigoid",
        "id": 132819276,
        "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/02/Picture5.jpg",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.",
        "url": "https://finnhub.io/api/news?id=d78c6027549d97df0f74ab9917c3cd2b97e3ee76d5831abf5e04606e9355dcf9"
    },
    {
        "category": "company",
        "datetime": 1739866200,
        "headline": "American Century Focused Dynamic Growth Fund Q4 2024 Commentary",
        "id": 132767142,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/165180102/image_165180102.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "The reelection of former President Donald Trump initially pleased investors who had worried about another protracted legal battle regarding the election\u00e2\u0080\u0099s results.",
        "url": "https://finnhub.io/api/news?id=8d96f1a7ed9b70cba0740677fa661b9715838adf02954ff10196f42620bcc3bc"
    },
    {
        "category": "company",
        "datetime": 1739859000,
        "headline": "Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid",
        "id": 132773383,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid",
        "url": "https://finnhub.io/api/news?id=8daf980f279be2d29c8f95def1cae13ec1f064b2605c6cb27bb812e108432f3d"
    },
    {
        "category": "company",
        "datetime": 1739858340,
        "headline": "Dupixent\u00ae (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)",
        "id": 132819278,
        "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placebo BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions TARRYTOWN, N.Y. and PARIS,",
        "url": "https://finnhub.io/api/news?id=03cdfe7c448c465da25de59d86f7acfff1a67eded72b1281ee86e6db1fd0ac5e"
    },
    {
        "category": "company",
        "datetime": 1739742843,
        "headline": "Why Regeneron's Price May Soon Break Out",
        "id": 132742765,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398811731/image_1398811731.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top pick for long-term investors.",
        "url": "https://finnhub.io/api/news?id=d5af37c15f7937cb7659c25bbaefc15e6d819270430ea1e30992e3c141a5a315"
    },
    {
        "category": "company",
        "datetime": 1739541540,
        "headline": "Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y",
        "id": 132819279,
        "image": "https://media.zenfs.com/en/zacks.com/004265dfd2737a0262868ee5a83c126c",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales.",
        "url": "https://finnhub.io/api/news?id=eef3716614ab929ea8edd1a50980df019e399d2780d366899082dc9a1195d9fc"
    },
    {
        "category": "company",
        "datetime": 1739480280,
        "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q4 2024 Commentary",
        "id": 132709614,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172483014/image_172483014.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "The Portfolio returned -10.75% (gross) and the MSCI World Health Care IndexSM returned -11.32%. Read more here.",
        "url": "https://finnhub.io/api/news?id=8d306981723ae6baaa27a41df72a2ad77528d2ff9fae45eee20d34b6483d2dcd"
    },
    {
        "category": "company",
        "datetime": 1739468968,
        "headline": "Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain",
        "id": 132709074,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Kiniksa Pharmaceuticals stock is attractive because it trades near 52-week lows, and its marketed drug gains traction. Click to find out why KNSA is a Hold.",
        "url": "https://finnhub.io/api/news?id=5d90ca30706ab51288585963e09287df18a5bd0de91ce97d5e6f55d739ca71ee"
    },
    {
        "category": "company",
        "datetime": 1739455213,
        "headline": "Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 11% CAGR delivered to shareholders",
        "id": 132819281,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "While Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders are probably generally happy, the stock hasn't had...",
        "url": "https://finnhub.io/api/news?id=6b421adbe611cfaf881f97fe98554a56b7199b3ca08d166e08c9db76dfef8a7c"
    },
    {
        "category": "company",
        "datetime": 1739392800,
        "headline": "Janus Henderson Global Life Sciences Fund Q4 2024 Commentary",
        "id": 132698753,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205585/image_1322205585.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=10b10afe2a805029d7ce2f9c8b1ec10ce14300270ce9d50ee7971586c5474449"
    },
    {
        "category": "company",
        "datetime": 1739307900,
        "headline": "Regeneron Announces Investor Conference Presentations",
        "id": 132819283,
        "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at 11:50 a.m. ET on Tuesday, March 4, 2025Leerink Partners 2025 Global Healthcare Conference at 8:00 a.m. ET on Tuesday, March 11, 2025 The sessions may be accessed from the \"Investors & Media\" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of",
        "url": "https://finnhub.io/api/news?id=155e73048421f22255f8ab8c20965a9b718905ba690c0b6cbd281b7f6b766b10"
    },
    {
        "category": "company",
        "datetime": 1739275200,
        "headline": "Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma",
        "id": 132819285,
        "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least fo",
        "url": "https://finnhub.io/api/news?id=acebe50614400c05ab8403446aca53640f880d23cc18d17999618e83f1cecc32"
    },
    {
        "category": "company",
        "datetime": 1739259360,
        "headline": "Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma",
        "id": 132664048,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma",
        "url": "https://finnhub.io/api/news?id=e8e5dd3aa4d4ac9d9f4bf3966d15856b777bfb9bf529df9706bf0f7e0c47b83c"
    },
    {
        "category": "company",
        "datetime": 1739204508,
        "headline": "Regeneron\u2019s macular oedema therapy shows promise in Phase III trial",
        "id": 132819286,
        "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2025/02/CTA-3-Regeneron-shutterstock_2148333613-1.jpg",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.",
        "url": "https://finnhub.io/api/news?id=938a0134f860bba6a4d7fbb91d7d3842c4f6f947c79c88cdc5fb1e24baae14eb"
    },
    {
        "category": "company",
        "datetime": 1739199300,
        "headline": "Celldex Therapeutics: Will They Get It Right After A Decade Of Failures?",
        "id": 132635333,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.",
        "url": "https://finnhub.io/api/news?id=ca0d6c4c06f2ecff9cb2fe5eff01d3f52d5d49b02ffefac8031fa444e0d316f9"
    },
    {
        "category": "company",
        "datetime": 1739186100,
        "headline": "Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move",
        "id": 132660381,
        "image": "https://g.foolcdn.com/editorial/images/806140/scientist-altering-dna-genome-project.jpg",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover.  While it can be hard to separate the wheat from the chaff, let's consider three companies, all in the biotech industry, that were market losers last year but could recover given enough time: CRISPR Therapeutics (NASDAQ: CRSP), Amgen (NASDAQ: AMGN), and Regeneron (NASDAQ: REGN).  CRISPR Therapeutics is the gene-editing specialist that created Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals.",
        "url": "https://finnhub.io/api/news?id=9b23cf8ee82cda98a382430d4fb49a419c19f9ed37e368ab695a6b96a2d1d034"
    },
    {
        "category": "company",
        "datetime": 1739109622,
        "headline": "Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock",
        "id": 132819289,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...",
        "url": "https://finnhub.io/api/news?id=1c568381ca1a2d0b5cfed8527b933dcf3e28a9afd90d244cf4bd88c54a28f924"
    },
    {
        "category": "company",
        "datetime": 1739106130,
        "headline": "Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow",
        "id": 132819292,
        "image": "https://s.yimg.com/ny/api/res/1.2/cIduwTpvf58tjDO9.yfm_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/stockstory_922/dd5ed23043756cdda4b65d5c228863e0",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here\u2019s what to expect.",
        "url": "https://finnhub.io/api/news?id=235cbefbc2ef3f4789ea3b91cc5c84daca24465e087c34fdcd95b75ce6b89cbf"
    },
    {
        "category": "company",
        "datetime": 1739054400,
        "headline": "EYLEA HD\u00ae (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting",
        "id": 132819294,
        "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA\u00ae (aflibercept) Injection 2 mg dosed every 4 weeksTARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD\u00ae (aflibercept) Injection 8 mg for the treatment of patients with macular edema followin",
        "url": "https://finnhub.io/api/news?id=eeb76fae79335b54d898e9c2eb43048533598d7c4d7189306d70d1e8cbf64114"
    },
    {
        "category": "company",
        "datetime": 1739048100,
        "headline": "Three-Year Results for EYLEA HD\u00ae (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals",
        "id": 132819296,
        "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%, 58%, 40% and 24% achieved last assigned dosing intervals of \u22653, \u22654, \u22655 and 6 months, respectively At three years, the vast majority of patients who switched to EYLEA HD from a fixed 2-month dosing regimen with EYLEA\u00ae (aflibercept) Injection 2 mg maintained visual and anatomic improvements while rapidly",
        "url": "https://finnhub.io/api/news?id=79bd2e8a298637764c1613774c9fc6e5b1ac4673a022a37c9e1e36f09d75eeb8"
    },
    {
        "category": "company",
        "datetime": 1738794900,
        "headline": "Fidelity Contrafund Q4 2024 Review",
        "id": 132569795,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/952762622/image_952762622.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "For Q4 2024, the Fidelity Contrafund's Retail Class shares gained 3.56%, topping the 2.41% advance of the S&P 500\u00c2\u00ae index. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=3a0a5a73483fa9fd7e332d0b4cf17231696a722fb5cfb954e54a0be6eb6011ff"
    },
    {
        "category": "company",
        "datetime": 1738774020,
        "headline": "Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval",
        "id": 132601926,
        "image": "https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "REGN and AMGN are in the spotlight this week on fourth-quarter earnings release.",
        "url": "https://finnhub.io/api/news?id=d2ff6b9a20204a5e2c275a0de09a1e4c1bb5f32a4c807d155d5bf57456f03b0f"
    },
    {
        "category": "company",
        "datetime": 1738773720,
        "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
        "id": 132579350,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
        "url": "https://finnhub.io/api/news?id=8390e5db24a24d944e92c4c7bb55fc1f778c797f1f1e91a5c96ef946bba97ac3"
    },
    {
        "category": "company",
        "datetime": 1738761030,
        "headline": "Regeneron Is Playing Defense With Capital Allocation",
        "id": 132563616,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2129856936/image_2129856936.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read why I rate REGN a Buy.",
        "url": "https://finnhub.io/api/news?id=9a0c9b25731d76b789ce893a51dade7a12e0b641dc763a1ebb21f152d7bed54c"
    },
    {
        "category": "company",
        "datetime": 1738754880,
        "headline": "Amgen obesity drug on hold; Regeneron sets first dividend",
        "id": 132601927,
        "image": "https://imgproxy.divecdn.com/EK5xKj0ydykvmwFmBqsauREtdhrHAUsAiyI6JgDkO1s/g:nowe:0:0/c:1207:682/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDgzOTIxNzkzLmpwZw==.webp",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore \u201cstrategic alternatives.\u201d",
        "url": "https://finnhub.io/api/news?id=31f9129bfee32c4aad47fee283251380f8439f1b64f7d6fb163433405683aba9"
    },
    {
        "category": "company",
        "datetime": 1738754836,
        "headline": "Regeneron Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations",
        "id": 132601928,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN ) Full Year 2024 Results Key Financial Results Revenue: US$14.2b (up 8.3% from...",
        "url": "https://finnhub.io/api/news?id=48ee5500c238b39e29f999b2f94b6bbd195976602016b64a05569cc05fbf5edb"
    },
    {
        "category": "company",
        "datetime": 1738752060,
        "headline": "Company News for Feb 5, 2025",
        "id": 132601929,
        "image": "https://media.zenfs.com/en/zacks.com/7c4df663699c823ba05ae4b84ac121f2",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Companies In The News Are: RACE, REGN, MPLX, WEC.",
        "url": "https://finnhub.io/api/news?id=fb3aea79dae66df957866bfac77960955679ead5e61c3125701486ae802d21b5"
    },
    {
        "category": "company",
        "datetime": 1738746600,
        "headline": "Fidelity Blue Chip Growth Fund Q4 2024 Commentary",
        "id": 132562503,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397047877/image_1397047877.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "For Q4 2024, the Fidelity Blue Chip Growth Fund's Retail Class shares gained 9.12%, handily outpacing the benchmark. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=3fe7acc1f518c5b79647875f00651e8380ca832b0db7920c13dff2215f8c56ae"
    },
    {
        "category": "company",
        "datetime": 1738741500,
        "headline": "Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings",
        "id": 132561931,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for LIBTAYO in 2024. Read more here.",
        "url": "https://finnhub.io/api/news?id=6d053d8b0c2de44e8e9fd79d0e6f7e54589c26a8066a4091d94f87302426f94f"
    },
    {
        "category": "company",
        "datetime": 1738739237,
        "headline": "Regeneron Pharmaceuticals Inc (REGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...",
        "id": 132601930,
        "image": "https://media.zenfs.com/en/us.finance.gurufocus/c93aacc12a21c50f59b9851494e471ec",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new strategic moves including dividend initiation and share repurchase authorization.",
        "url": "https://finnhub.io/api/news?id=47161f76119e89e50c9cc3ac8a563c97505926d2040ea45456dc84e94a7b4abc"
    },
    {
        "category": "company",
        "datetime": 1738736721,
        "headline": "Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call",
        "id": 132601931,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call",
        "url": "https://finnhub.io/api/news?id=a0e8c569d8a2072081d885107302b95b2db900ac5c9729a7d07d8ce399bd88dc"
    },
    {
        "category": "company",
        "datetime": 1738712682,
        "headline": "Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday",
        "id": 132601932,
        "image": "https://g.foolcdn.com/editorial/images/806486/two-people-in-white-lab-coats-looking-at-a-computer-display.jpg",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week.  Regeneron's price zoomed well higher than the S&P 500 index's trajectory, which was a rise of 0.7% on the day.  The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion.",
        "url": "https://finnhub.io/api/news?id=8e472d97031bfc843b533fc763b17ff5486d8584e2b553a96dbcfc4f9e41b3e4"
    },
    {
        "category": "company",
        "datetime": 1738703510,
        "headline": "Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend",
        "id": 132601933,
        "image": "https://media.zenfs.com/en/ibd.com/b727993c80cd23c03b1f42c9321ae4f1",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.",
        "url": "https://finnhub.io/api/news?id=867252a6d8ec518d9d0f47b11cbb835fb2bd2b858053193c6afbb56fb704eba0"
    },
    {
        "category": "company",
        "datetime": 1738694880,
        "headline": "Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend",
        "id": 132601934,
        "image": "https://media.zenfs.com/en/zacks.com/9137c6f6ed305652874fd6a3a724cf37",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition. The company initiates a dividend program,",
        "url": "https://finnhub.io/api/news?id=06614d84f80b95282fef2b2f57a9fadef6a34cc5c22172d978f577f56f47c8a0"
    },
    {
        "category": "company",
        "datetime": 1738693238,
        "headline": "MAIA\u2019s lung cancer therapy 99% more likely to improve OS over chemo alone",
        "id": 132601935,
        "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2025/02/shutterstock_2235117017-4.jpg",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "In the Phase II trial, THIO improved patients\u2019 overall survival when taken in combination with Libtayo.",
        "url": "https://finnhub.io/api/news?id=7756d7fd40a9b0b30ffef8f512f373468a31e918f6ad6989b7de0777ea3b4d20"
    },
    {
        "category": "company",
        "datetime": 1738688560,
        "headline": "Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program",
        "id": 132601936,
        "image": "https://media.zenfs.com/en/Benzinga/c123c38f55ed5a65179917bbee8e6942",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the consensus of $11.29. The company reported sales of $3.79 billion, up 10%, beating the consensus of $3.75 billion. \u201cRegeneron\u2019s financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurch",
        "url": "https://finnhub.io/api/news?id=dce8d2b4e74d2aa1acbcacdfaa935b34ee87596e270681f2c4fffc5dcfcf3a17"
    },
    {
        "category": "company",
        "datetime": 1738679738,
        "headline": "Is Regeneron Pharmaceuticals (REGN) the Best Cancer Stock to Buy According to Hedge Funds?",
        "id": 132601937,
        "image": "https://s.yimg.com/ny/api/res/1.2/jMekiCT4mZ2_S7szsjNT5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best cancer stocks to buy. Overview of the Global Oncology Sector Cancer is the second leading cause of death [\u2026]",
        "url": "https://finnhub.io/api/news?id=899a7ab4741445abb6b7870776867df6cb1abaa29eaa2642db2de398c95a3aca"
    },
    {
        "category": "company",
        "datetime": 1738679713,
        "headline": "Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025",
        "id": 132553270,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/108129910/image_108129910.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what makes REGN stock a compelling buy.",
        "url": "https://finnhub.io/api/news?id=dc03facd2514a9da346ce602a1a92165fed09beffa9f3f7f05b05c259f300c52"
    },
    {
        "category": "company",
        "datetime": 1738679425,
        "headline": "Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics",
        "id": 132601938,
        "image": "https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
        "url": "https://finnhub.io/api/news?id=bb7696636484683e5f34b14781deaa9b41a3a43c65089f35b5e5fe6801b8b7e0"
    },
    {
        "category": "company",
        "datetime": 1738674922,
        "headline": "Regeneron beats quarterly estimates on eczema drug demand; launches dividend program",
        "id": 132601939,
        "image": "https://media.zenfs.com/en/reuters-finance.com/1c2053605d401fe68094e051d1ee91ac",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program, sending its shares up 2.2% premarket. U.S. sales of Eylea, which has been its long-standing cash cow, rose by 2% to $1.5 billion, including $305 million from the higher 8-milligram dose version. Analysts were expecting $1.77 billion in total Eylea sales, according to LSEG data.",
        "url": "https://finnhub.io/api/news?id=f6ed47cb815a5ac1f59eb0c588755ab080b3e43465e3574703bda8d40c1f0df7"
    },
    {
        "category": "company",
        "datetime": 1738674240,
        "headline": "Regeneron\u2019s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea",
        "id": 132549619,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron\u2019s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea",
        "url": "https://finnhub.io/api/news?id=23cef771086a9032d45821b34c76dff56f8fe4cf7c02a7ad4630a0986de274b3"
    },
    {
        "category": "company",
        "datetime": 1738673104,
        "headline": "Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates",
        "id": 132601940,
        "image": "https://s.yimg.com/ny/api/res/1.2/gZA5XMnsr1RRZw6lGNAcdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD05NDA-/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Regeneron (REGN) delivered earnings and revenue surprises of 3.87% and 0.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
        "url": "https://finnhub.io/api/news?id=d5c0c79612dc0a6160532430f42054c070542d5130bb2dc987199b174632b1d9"
    },
    {
        "category": "company",
        "datetime": 1738670058,
        "headline": "Regeneron: Q4 Earnings Snapshot",
        "id": 132601941,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "On a per-share basis, the Tarrytown, New York-based company said it had profit of $8.06. Earnings, adjusted for stock option expense and non-recurring costs, were $12.07 per share. The results beat Wall Street expectations.",
        "url": "https://finnhub.io/api/news?id=a118d91426abc7cb28b85c93e8b80ce3adb9a4162634af25dc9493f0cc53f852"
    },
    {
        "category": "company",
        "datetime": 1738669607,
        "headline": "Regeneron\u2019s (NASDAQ:REGN) Q4 Sales Top Estimates, Stock Soars",
        "id": 132601942,
        "image": "https://s.yimg.com/ny/api/res/1.2/Vkx43ET44Ukm4snbdwReLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market\u2019s revenue expectations, with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per share was 7.8% above analysts\u2019 consensus estimates.",
        "url": "https://finnhub.io/api/news?id=bf7693d97ad4c89402c542fc87c6622e3f998f415998510cd3bd28a4bb33d379"
    },
    {
        "category": "company",
        "datetime": 1738668856,
        "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Q4 2024 Earnings Call Transcript",
        "id": 132543620,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Conference Call February 4, 2025 8:30 AM ETCompany ParticipantsRyan Crowe - SVP, IRLeonard...",
        "url": "https://finnhub.io/api/news?id=6a5557f820ac4b02231d48795d7a81de4b4b40acac843e24d7edca3975b846a6"
    },
    {
        "category": "company",
        "datetime": 1738668600,
        "headline": "Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion",
        "id": 132601943,
        "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Fourth quarter 2024 revenues increased 10% to $3.79 billion versus fourth quarter 2023Full year 2024 revenues increased 8% to $14.20 billion versus 2023; excluding RonapreveTM(a)(b), revenues increased 10%Fourth quarter 2024 Dupixent\u00ae global net sales (recorded by Sanofi) increased 15% to $3.70 billion versus fourth quarter 2023; full year 2024 Dupixent global net sales increased 22% to $14.15 billion versus 2023Fourth quarter 2024 U.S. net sales for EYLEA HD\u00ae and EYLEA\u00ae increased 2% versus four",
        "url": "https://finnhub.io/api/news?id=b93591b8aefe33115b051e40ac7a2ae6e4063bfa66ed6ac80fc0b622ebc07c89"
    },
    {
        "category": "company",
        "datetime": 1738653264,
        "headline": "Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD",
        "id": 132542441,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "By Rob Curran Regeneron Pharmaceuticals logged a sharp increase in fourth-quarter revenue amid strong demand for a new formulation of its EYLEA product. The biotechnology company posted...",
        "url": "https://finnhub.io/api/news?id=60562d139acdf121531d6795a414a54a3fd68cc1dfbc1d210ed5229c9d0e2262"
    },
    {
        "category": "company",
        "datetime": 1738653074,
        "headline": "Regeneron Launches Dividend Program, Boost Stock Buybacks",
        "id": 132542436,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "By Colin Kellaher Regeneron Pharmaceuticals is stepping up its shareholder returns with the launch of a quarterly dividend and a $3 billion increase to its stock-buyback program. Regeneron on...",
        "url": "https://finnhub.io/api/news?id=3a2cb5014ca59437487950eb4fcb0cf26778b41748ed3467a82433604ff19bf5"
    },
    {
        "category": "company",
        "datetime": 1738652280,
        "headline": "Regeneron 4Q Rev Up on Strong Sales of EYLEA HD",
        "id": 132549620,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Regeneron 4Q Rev Up on Strong Sales of EYLEA HD",
        "url": "https://finnhub.io/api/news?id=3f706cdadc55b24a19eefea1440aafb515f237173fce78ce18b728c02e6317cf"
    },
    {
        "category": "company",
        "datetime": 1738648510,
        "headline": "Alphabet results lead busy day of earnings",
        "id": 132543886,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "Alphabet results lead busy day of earnings",
        "url": "https://finnhub.io/api/news?id=e5dfd889369f51d42634e6a306820faabbe83decbd89331f4eace874326224f3"
    },
    {
        "category": "company",
        "datetime": 1738647981,
        "headline": "Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN",
        "id": 132541886,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Feb. 4, 2025 /PRNewswire/ --\u00a0Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
        "url": "https://finnhub.io/api/news?id=61444561d916bed187a7fdb0514f7a08ced60d64b91e698b36f58614803b1cf1"
    },
    {
        "category": "company",
        "datetime": 1738500666,
        "headline": "Why Are Analysts Bullish on Regeneron Pharmaceuticals, Inc. (REGN) Now?",
        "id": 132601944,
        "image": "https://s.yimg.com/ny/api/res/1.2/jMekiCT4mZ2_S7szsjNT5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain of [\u2026]",
        "url": "https://finnhub.io/api/news?id=c74c80e4ade1c4b2b0c0bc51d5789a9509b86d377d6083066cbe6685ab599571"
    },
    {
        "category": "company",
        "datetime": 1738347660,
        "headline": "Regeneron to Report Q4 Earnings: Is a Beat in the Cards?",
        "id": 132601945,
        "image": "https://media.zenfs.com/en/zacks.com/004265dfd2737a0262868ee5a83c126c",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter 2024 results soon.",
        "url": "https://finnhub.io/api/news?id=ca424689774a91dd02ac66e6def0b0ee19ea72af00f138376970f0053b63c70d"
    },
    {
        "category": "company",
        "datetime": 1738302378,
        "headline": "Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN",
        "id": 132503758,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Levi &\u00a0Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
        "url": "https://finnhub.io/api/news?id=4943977030c984ca610af301c294c165c3867416e5499a6d2c75df197f130cab"
    },
    {
        "category": "company",
        "datetime": 1738294200,
        "headline": "It\u2019s Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders.",
        "id": 134152123,
        "image": "",
        "related": "REGN",
        "source": "MarketWatch",
        "summary": "It\u2019s Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders.",
        "url": "https://finnhub.io/api/news?id=2cd9207857ff44cd6d4ace04e323f1cbf6009cca73056b3b89d73d4ad847d0e9"
    },
    {
        "category": "company",
        "datetime": 1738215979,
        "headline": "The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN",
        "id": 132498127,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Jan. 30, 2025 /PRNewswire/ --\u00a0The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
        "url": "https://finnhub.io/api/news?id=f1c8b26cd56e422c24ef0719ba22014a9b0892310270ed9c9d1a2ab1dc68d18c"
    },
    {
        "category": "company",
        "datetime": 1738101673,
        "headline": "Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN",
        "id": 132489508,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc.\u00a0\u00a0. Such investors are advised to contact Danielle...",
        "url": "https://finnhub.io/api/news?id=6e35b6bde4c215db11b0d807ac2cc49e76b6a8c050618e391ec0420ebc3a32fa"
    },
    {
        "category": "company",
        "datetime": 1738076400,
        "headline": "Drugmakers Show Restraint on Price Increases in New Trump Era",
        "id": 132521086,
        "image": "",
        "related": "REGN",
        "source": "DowJones",
        "summary": "Drugmakers Show Restraint on Price Increases in New Trump Era",
        "url": "https://finnhub.io/api/news?id=f17a76ce54722d42e46d57502373ff6b6b7457c0b31bbeec482cfbcfe634f5e6"
    },
    {
        "category": "company",
        "datetime": 1737956780,
        "headline": "Contact The Gross Law Firm by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)",
        "id": 132478245,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Jan. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of\u00a0Regeneron Pharmaceuticals, Inc. . ...",
        "url": "https://finnhub.io/api/news?id=72af16e1e7ed28365752875a71440ac2a930ee4b5aed31cfeb1d7e95ce87a64e"
    },
    {
        "category": "company",
        "datetime": 1737792000,
        "headline": "5 Best CEFs This Month For Nearly 10% Yield (January 2025)",
        "id": 132468888,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310121198/image_1310121198.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Discover high-yield closed-end funds for income investors with reasonable total returns. Click for our process of winnowing out the best CEFS this month.",
        "url": "https://finnhub.io/api/news?id=197c5be575be03a4b9586b3090506ccae90f12a685d42c55c0010fb160219701"
    },
    {
        "category": "company",
        "datetime": 1737722312,
        "headline": "Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Falling Stock to Invest in Right Now?",
        "id": 132456939,
        "image": "https://s.yimg.com/ny/api/res/1.2/jMekiCT4mZ2_S7szsjNT5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best falling stocks to invest in right now. The overall stock market has been in an uptrend, as depicted by major [\u2026]",
        "url": "https://finnhub.io/api/news?id=385bd889856a03cefdc12b128607f13cdf709b4aacbb3c291c2817e9a054bcc3"
    },
    {
        "category": "company",
        "datetime": 1737697580,
        "headline": "Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN",
        "id": 132453725,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
        "url": "https://finnhub.io/api/news?id=1e694e9d02372f5cf1cafb1084a150f18582f11723200a8dead33a893c8263c6"
    },
    {
        "category": "company",
        "datetime": 1737651720,
        "headline": "America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search",
        "id": 132456940,
        "image": "https://media.zenfs.com/en/prnewswire.com/fc326aeaddb5e0a1df18cf4b26757020",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in the 2025 Regeneron Science Talent Search (STS), the U.S.'s longest-running and most distinguished science, technology, engineering and math (STEM) competition for high school seniors.",
        "url": "https://finnhub.io/api/news?id=6e655450f4820d18b959ea6f135b805390420da993b7d99b91153a6a6aa3705e"
    },
    {
        "category": "company",
        "datetime": 1737646084,
        "headline": "ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN",
        "id": 132450244,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. between November 2, 2023 and October 30, 2024, both dates inclusive , of...",
        "url": "https://finnhub.io/api/news?id=245e884718c392029aaa155b60520e2340377e8011f76ece807749fec2ebcd1a"
    },
    {
        "category": "company",
        "datetime": 1737644524,
        "headline": "INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals",
        "id": 132450153,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "Faruqi & Faruqi, LLP Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their OptionsIf you...",
        "url": "https://finnhub.io/api/news?id=d6972d63c75f4eae68219e7fa405ac1e06c3ff28e3f50e54e0c1c63fb8da8126"
    },
    {
        "category": "company",
        "datetime": 1737633663,
        "headline": "America\u2019s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search",
        "id": 132449425,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "The Regeneron Science Talent Search Celebrates and Rewards Today\u2019s Most Talented Young Minds Driving Innovation and Progress through Scientific ExplorationTARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. ...",
        "url": "https://finnhub.io/api/news?id=02c3ac97babe5de33e7ce265a3de82b4598645d47eec49d19a7cffd1416db730"
    },
    {
        "category": "company",
        "datetime": 1737611180,
        "headline": "Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm",
        "id": 132447422,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Jan. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
        "url": "https://finnhub.io/api/news?id=c10f8a416c4f0ccc616bcd7821708210f5d0cfac1b48eda9ebc0c0d507ad7d3e"
    },
    {
        "category": "company",
        "datetime": 1737577025,
        "headline": "Robbins LLP Reminds REGN Shareholders to Seek Counsel for the Regeneron Pharmaceuticals, Inc. Class Action",
        "id": 132445158,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "SAN DIEGO, Jan. 22, 2025 /PRNewswire/ -- Robbins LLP\u00a0reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron...",
        "url": "https://finnhub.io/api/news?id=5bd97c35f1fd7c9b38747160d9de041d1aa435aac0372c3d8dab0439d87f5d44"
    },
    {
        "category": "company",
        "datetime": 1737546300,
        "headline": "Dodge & Cox Stock Fund Q4 2024 Shareholder Letter",
        "id": 132443102,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/874979248/image_874979248.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Stocks surged in November after President Donald Trump won the U.S. election and Republicans won majorities in both the Senate and House of Representatives.",
        "url": "https://finnhub.io/api/news?id=d96af1938511d69a06d2b2732cc0f5720c9a0ecf0486fa7caa9dba9a72c7d411"
    },
    {
        "category": "company",
        "datetime": 1737543300,
        "headline": "Baron Health Care Fund Q4 2024 Shareholder Letter",
        "id": 132442862,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Baron Health Care Fund retreated in the fourth quarter of 2024, in line with its benchmark, the Russell 3000 Health Care Index. Read more here.",
        "url": "https://finnhub.io/api/news?id=0271890740cb4d946feb67364f9ef0cbee944c4e8517254a2ede741d5201d864"
    },
    {
        "category": "company",
        "datetime": 1737488100,
        "headline": "REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES",
        "id": 132439101,
        "image": "https://media.zenfs.com/en/cnwgroup.com/6487cca738d51bbd331bdcde98a51337",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Regeneron Canada Company today officially opened its first headquarters that will allow it to better serve the needs of Canadian patients who may benefit from its life-transforming, innovative medicines for serious diseases.",
        "url": "https://finnhub.io/api/news?id=0303691016ef37e82457adf7da9012e1c4ea1af34e252806dc1d7f935bc426cd"
    },
    {
        "category": "company",
        "datetime": 1737475263,
        "headline": "REGN Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit",
        "id": 132438007,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. and...",
        "url": "https://finnhub.io/api/news?id=5b6a7fb6e9bc07d3d5de9f7ba48a0fafede75d5f08b198df188b68919830ff7e"
    },
    {
        "category": "company",
        "datetime": 1737438383,
        "headline": "Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN",
        "id": 132435009,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
        "url": "https://finnhub.io/api/news?id=0afb1d215a750f70e3ba736fd3a0ece09c258c2deaa7363fcd10680937640220"
    },
    {
        "category": "company",
        "datetime": 1737305685,
        "headline": "Top 4 Immunology Stocks Poised For Growth In 2025",
        "id": 132426490,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413108793/image_1413108793.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "Discover the latest trends and developments in the global immunology drugs market, along with four promising stocks to watch for potential investments.",
        "url": "https://finnhub.io/api/news?id=89d92fb4873b2558c4d0f5f75610a8a4ee6050f99c0d8d2410f07380589e1d07"
    },
    {
        "category": "company",
        "datetime": 1737285459,
        "headline": "Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): \u2018This Company Has Never Lost Its Ability To Develop New Medicines\u2019",
        "id": 132439103,
        "image": "https://s.yimg.com/ny/api/res/1.2/jMekiCT4mZ2_S7szsjNT5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 9 Stocks on Jim Cramer\u2019s Radar. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks on Jim Cramer\u2019s radar. Jim Cramer, host of Mad Money, recently emphasized the importance of long-term investing, urging investors to focus on [\u2026]",
        "url": "https://finnhub.io/api/news?id=9411f068593d02e4f2632df8f585bd6f0242d4fb85408a98cc5f1d2459b7892d"
    },
    {
        "category": "company",
        "datetime": 1737122412,
        "headline": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
        "id": 132439104,
        "image": "https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
        "url": "https://finnhub.io/api/news?id=09704fc3049dec90c3c1157827fc8ea521cb621193cc7e11244ac6ef2a7d863a"
    },
    {
        "category": "company",
        "datetime": 1737097920,
        "headline": "The Zacks Analyst Blog Moderna, Regeneron, Intellia  Sage and GSK",
        "id": 132421344,
        "image": "https://media.zenfs.com/en/zacks.com/9e8d93e17a792e7de990e3344e61fa6a",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.",
        "url": "https://finnhub.io/api/news?id=83c97c74570ba9ce7a97e3c915b49f4775078b77a801441f21f6252ea7af193b"
    },
    {
        "category": "company",
        "datetime": 1737092781,
        "headline": "Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN",
        "id": 132413968,
        "image": "",
        "related": "REGN",
        "source": "Finnhub",
        "summary": "NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
        "url": "https://finnhub.io/api/news?id=09c04ed76b1807e79fec35d31314a77c307ac519e707367de3c0d6735a070c24"
    },
    {
        "category": "company",
        "datetime": 1737068100,
        "headline": "Baird Q4 2024 International And Global Growth Fund Commentary",
        "id": 132412293,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163930695/image_1163930695.jpg?io=getty-c-w1536",
        "related": "REGN",
        "source": "SeekingAlpha",
        "summary": "In the fourth quarter of 2024, the Baird Chautauqua International Growth Fund Net Investor Class returned -4.31%, outperforming the MSCI ACWI ex-U.S. Index\u00c2\u00ae ND, which returned -7.60%.",
        "url": "https://finnhub.io/api/news?id=d6d6283252f961c1956b4e9b204d925bd8cffd09caaa15b4e93b18ba3b17000c"
    },
    {
        "category": "company",
        "datetime": 1737046800,
        "headline": "Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates",
        "id": 132439107,
        "image": "https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307",
        "related": "REGN",
        "source": "Yahoo",
        "summary": "MRNA and NTLA are down this week after providing financial and strategic updates.",
        "url": "https://finnhub.io/api/news?id=7d82301d9b9fcca0f9cc9ad4e7a3e21da75941e45505b24658a2da5b28052a91"
    }
]